Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Identification of a receptor-binding region in the core segment of the human anaphylatoxin C5a.

Vlattas I, Sytwu II, Dellureficio J, Stanton J, Braunwalder AF, Galakatos N, Kramer R, Seligmann B, Sills MA, Wasvary J.

J Med Chem. 1994 Aug 19;37(17):2783-90.

PMID:
8064805
2.

Site-specific mutagenesis of residues in the human C5a anaphylatoxin which are involved in possible interaction with the C5a receptor.

Bubeck P, Grötzinger J, Winkler M, Köhl J, Wollmer A, Klos A, Bautsch W.

Eur J Biochem. 1994 Feb 1;219(3):897-904.

3.

Identification and synthesis of a receptor binding site of human anaphylatoxin C5a.

Kawai M, Quincy DA, Lane B, Mollison KW, Luly JR, Carter GW.

J Med Chem. 1991 Jul;34(7):2068-71.

PMID:
2066977
4.

Residues 21-30 within the extracellular N-terminal region of the C5a receptor represent a binding domain for the C5a anaphylatoxin.

Chen Z, Zhang X, Gonnella NC, Pellas TC, Boyar WC, Ni F.

J Biol Chem. 1998 Apr 24;273(17):10411-9.

6.

Biologically active conformer of the effector region of human C5a and modulatory effects of N-terminal receptor binding determinants on activity.

Finch AM, Vogen SM, Sherman SA, Kirnarsky L, Taylor SM, Sanderson SD.

J Med Chem. 1997 Mar 14;40(6):877-84.

PMID:
9083476
7.
8.

The amino terminus of the human C5a receptor is required for high affinity C5a binding and for receptor activation by C5a but not C5a analogs.

DeMartino JA, Van Riper G, Siciliano SJ, Molineaux CJ, Konteatis ZD, Rosen H, Springer MS.

J Biol Chem. 1994 May 20;269(20):14446-50.

9.

Structure-function studies in a series of carboxyl-terminal octapeptide analogues of anaphylatoxin C5a.

Kawai M, Quincy DA, Lane B, Mollison KW, Or YS, Luly JR, Carter GW.

J Med Chem. 1992 Jan 24;35(2):220-3.

PMID:
1732540
11.

Analysis of the C5a anaphylatoxin core domain using a C5a phage library selected on differentiated U937 cells.

Kola A, Baensch M, Bautsch W, Klos A, Köhl J.

Mol Immunol. 1999 Feb;36(2):145-52.

PMID:
10378686
12.
13.

Antagonistic peptides against human anaphylatoxin C5a.

Kaneko Y, Okada N, Baranyi L, Azuma T, Okada H.

Immunology. 1995 Sep;86(1):149-54.

14.

Sulfated tyrosines contribute to the formation of the C5a docking site of the human C5a anaphylatoxin receptor.

Farzan M, Schnitzler CE, Vasilieva N, Leung D, Kuhn J, Gerard C, Gerard NP, Choe H.

J Exp Med. 2001 May 7;193(9):1059-66.

15.

Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a.

Finch AM, Wong AK, Paczkowski NJ, Wadi SK, Craik DJ, Fairlie DP, Taylor SM.

J Med Chem. 1999 Jun 3;42(11):1965-74.

PMID:
10354404
16.

Improvements in the minimum binding sequence of C5a: examination of His-67.

Or YS, Clark RF, Lane B, Mollison KW, Carter GW, Luly JR.

J Med Chem. 1992 Jan 24;35(2):402-6. No abstract available.

PMID:
1732557
17.

Structure-function relationships of human C5a and C5aR.

Huber-Lang MS, Sarma JV, McGuire SR, Lu KT, Padgaonkar VA, Younkin EM, Guo RF, Weber CH, Zuiderweg ER, Zetoune FS, Ward PA.

J Immunol. 2003 Jun 15;170(12):6115-24.

18.

Modeling molecular mechanisms of binding of the anaphylatoxin C5a to the C5a receptor.

Nikiforovich GV, Marshall GR, Baranski TJ.

Biochemistry. 2008 Mar 11;47(10):3117-30. doi: 10.1021/bi702321a. Epub 2008 Feb 15.

PMID:
18275159
19.

Site-directed mutagenesis of conserved charged residues in the helical region of the human C5a receptor. Arg2O6 determines high-affinity binding sites of C5a receptor.

Raffetseder U, Röper D, Mery L, Gietz C, Klos A, Grötzinger J, Wollmer A, Boulay F, Köhl J, Bautsch W.

Eur J Biochem. 1996 Jan 15;235(1-2):82-90.

Supplemental Content

Support Center